Gottesman M M, Hrycyna C A, Schoenlein P V, Germann U A, Pastan I
Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Annu Rev Genet. 1995;29:607-49. doi: 10.1146/annurev.ge.29.120195.003135.
The analysis of how human cancers evade chemotherapy has revealed a rich variety of cell-based genetic changes resulting in drug resistance. One of the best studied of these genetic alterations is increased expression of an ATP-dependent plasma membrane transport system, known as P-glycoprotein, or the multidrug transporter. This transporter actively effluxes a large number of natural product, hydrophobic, cytotoxic drugs, including many important anticancer agents. This review focuses on the genetic and molecular genetic analysis of the human multidrug transporter, including structure-function analysis, pre- and posttranslational regulation of expression, the role of gene amplification in increased expression, and the properties of transgenic and "knock-out" mice. One important feature of the MDR gene is its potential for the development of new selectable vectors for human gene therapy.
对人类癌症如何逃避化疗的分析揭示了多种基于细胞的基因变化,这些变化导致了耐药性。其中研究得最为透彻的基因改变之一是一种依赖ATP的质膜转运系统的表达增加,该系统被称为P-糖蛋白或多药转运蛋白。这种转运蛋白能主动外排大量天然产物、疏水性细胞毒性药物,包括许多重要的抗癌药物。这篇综述聚焦于人类多药转运蛋白的遗传学和分子遗传学分析,包括结构-功能分析、表达的翻译前和翻译后调控、基因扩增在表达增加中的作用,以及转基因和“基因敲除”小鼠的特性。多药耐药基因的一个重要特征是它有潜力开发用于人类基因治疗的新型选择载体。